271 related articles for article (PubMed ID: 35891355)
1. Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2.
Fiaschi L; Dragoni F; Schiaroli E; Bergna A; Rossetti B; Giammarino F; Biba C; Gidari A; Lai A; Nencioni C; Francisci D; Zazzi M; Vicenti I
Viruses; 2022 Jun; 14(7):. PubMed ID: 35891355
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis.
Tao K; Tzou PL; Kosakovsky Pond SL; Ioannidis JPA; Shafer RW
Microbiol Spectr; 2022 Aug; 10(4):e0092622. PubMed ID: 35700134
[TBL] [Abstract][Full Text] [Related]
3. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.
Bruel T; Hadjadj J; Maes P; Planas D; Seve A; Staropoli I; Guivel-Benhassine F; Porrot F; Bolland WH; Nguyen Y; Casadevall M; Charre C; Péré H; Veyer D; Prot M; Baidaliuk A; Cuypers L; Planchais C; Mouquet H; Baele G; Mouthon L; Hocqueloux L; Simon-Loriere E; André E; Terrier B; Prazuck T; Schwartz O
Nat Med; 2022 Jun; 28(6):1297-1302. PubMed ID: 35322239
[TBL] [Abstract][Full Text] [Related]
4. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
Sheward DJ; Kim C; Ehling RA; Pankow A; Castro Dopico X; Dyrdak R; Martin DP; Reddy ST; Dillner J; Karlsson Hedestam GB; Albert J; Murrell B
Lancet Infect Dis; 2022 Jun; 22(6):813-820. PubMed ID: 35305699
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.
Brehm TT; Pfefferle S; von Possel R; Karolyi M; Zoufaly A; Wichmann D; Kobbe R; Emmerich P; Nörz D; Aepfelbacher M; Schulze Zur Wiesch J; Addo MM; Schmiedel S; Lütgehetmann M
J Med Virol; 2022 Oct; 94(10):5038-5043. PubMed ID: 35662058
[TBL] [Abstract][Full Text] [Related]
6. Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19.
Mazzotta V; Cozzi-Lepri A; Colavita F; Lanini S; Rosati S; Lalle E; Mastrorosa I; Cimaglia C; Vergori A; Bevilacqua N; Lapa D; Mariano A; Bettini A; Agrati C; Piselli P; Girardi E; Castilletti C; Garbuglia AR; Vaia F; Nicastri E; Antinori A
Front Immunol; 2022; 13():868020. PubMed ID: 35514955
[TBL] [Abstract][Full Text] [Related]
7. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
Uraki R; Kiso M; Iida S; Imai M; Takashita E; Kuroda M; Halfmann PJ; Loeber S; Maemura T; Yamayoshi S; Fujisaki S; Wang Z; Ito M; Ujie M; Iwatsuki-Horimoto K; Furusawa Y; Wright R; Chong Z; Ozono S; Yasuhara A; Ueki H; Sakai-Tagawa Y; Li R; Liu Y; Larson D; Koga M; Tsutsumi T; Adachi E; Saito M; Yamamoto S; Hagihara M; Mitamura K; Sato T; Hojo M; Hattori SI; Maeda K; Valdez R; ; Okuda M; Murakami J; Duong C; Godbole S; Douek DC; Maeda K; Watanabe S; Gordon A; Ohmagari N; Yotsuyanagi H; Diamond MS; Hasegawa H; Mitsuya H; Suzuki T; Kawaoka Y
Nature; 2022 Jul; 607(7917):119-127. PubMed ID: 35576972
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies.
Bruel T; Stéfic K; Nguyen Y; Toniutti D; Staropoli I; Porrot F; Guivel-Benhassine F; Bolland WH; Planas D; Hadjadj J; Handala L; Planchais C; Prot M; Simon-Lorière E; André E; Baele G; Cuypers L; Mouthon L; Mouquet H; Buchrieser J; Sève A; Prazuck T; Maes P; Terrier B; Hocqueloux L; Schwartz O
Cell Rep Med; 2022 Dec; 3(12):100850. PubMed ID: 36450283
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters.
Uraki R; Kiso M; Imai M; Yamayoshi S; Ito M; Fujisaki S; Takashita E; Ujie M; Furusawa Y; Yasuhara A; Iwatsuki-Horimoto K; Sakai-Tagawa Y; Watanabe S; Hasegawa H; Kawaoka Y
Nat Microbiol; 2022 Aug; 7(8):1252-1258. PubMed ID: 35705860
[TBL] [Abstract][Full Text] [Related]
10. Serological fingerprints link antiviral activity of therapeutic antibodies to affinity and concentration.
Fiedler S; Devenish SRA; Morgunov AS; Ilsley A; Ricci F; Emmenegger M; Kosmoliaptsis V; Theel ES; Mills JR; Sholukh AM; Aguzzi A; Iwasaki A; Lynn AK; Knowles TPJ
Sci Rep; 2022 Nov; 12(1):19791. PubMed ID: 36396691
[TBL] [Abstract][Full Text] [Related]
11. Immune treatment in COVID-19.
Menéndez R; González P; Latorre A; Méndez R
Rev Esp Quimioter; 2022 Apr; 35 Suppl 1(Suppl 1):59-63. PubMed ID: 35488829
[TBL] [Abstract][Full Text] [Related]
12. Advances in the Omicron variant development.
Vitiello A; Ferrara F; Auti AM; Di Domenico M; Boccellino M
J Intern Med; 2022 Jul; 292(1):81-90. PubMed ID: 35289434
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies.
Arora P; Zhang L; Krüger N; Rocha C; Sidarovich A; Schulz S; Kempf A; Graichen L; Moldenhauer AS; Cossmann A; Dopfer-Jablonka A; Behrens GMN; Jäck HM; Pöhlmann S; Hoffmann M
Cell Host Microbe; 2022 Aug; 30(8):1103-1111.e6. PubMed ID: 35588741
[TBL] [Abstract][Full Text] [Related]
14. Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.
Ueno M; Iwata-Yoshikawa N; Matsunaga A; Okamura T; Saito S; Ashida S; Yoshida I; Nagashima M; Asakura H; Yaoita Y; Suzuki J; Sadamasu K; Yoshimura K; Kutsuna S; Shiwa-Sudo N; Nagata N; Suzuki T; Suzuki A; Okamoto M; Kimura M; Ohmagari N; Miura R; Ishizaka Y
Antiviral Res; 2022 May; 201():105297. PubMed ID: 35341809
[TBL] [Abstract][Full Text] [Related]
15. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains.
Case JB; Mackin S; Errico JM; Chong Z; Madden EA; Whitener B; Guarino B; Schmid MA; Rosenthal K; Ren K; Dang HV; Snell G; Jung A; Droit L; Handley SA; Halfmann PJ; Kawaoka Y; Crowe JE; Fremont DH; Virgin HW; Loo YM; Esser MT; Purcell LA; Corti D; Diamond MS
Nat Commun; 2022 Jul; 13(1):3824. PubMed ID: 35780162
[TBL] [Abstract][Full Text] [Related]
16. Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants.
Chen Z; Zhang P; Matsuoka Y; Tsybovsky Y; West K; Santos C; Boyd LF; Nguyen H; Pomerenke A; Stephens T; Olia AS; Zhang B; De Giorgi V; Holbrook MR; Gross R; Postnikova E; Garza NL; Johnson RF; Margulies DH; Kwong PD; Alter HJ; Buchholz UJ; Lusso P; Farci P
Cell Rep; 2022 Nov; 41(5):111528. PubMed ID: 36302375
[TBL] [Abstract][Full Text] [Related]
17. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
Zhang L; Poorbaugh J; Dougan M; Chen P; Gottlieb RL; Huhn G; Beasley S; Daniels M; Ngoc Vy Trinh T; Crisp M; Freitas JJ; Vaillancourt P; Patel DR; Nirula A; Kallewaard NL; Higgs RE; Benschop RJ
Front Immunol; 2021; 12():790469. PubMed ID: 34956222
[TBL] [Abstract][Full Text] [Related]
18. A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab.
Passariello M; Ferrucci V; Sasso E; Manna L; Lembo RR; Pascarella S; Fusco G; Zambrano N; Zollo M; De Lorenzo C
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628365
[TBL] [Abstract][Full Text] [Related]
19. Antibody evasion properties of SARS-CoV-2 Omicron sublineages.
Iketani S; Liu L; Guo Y; Liu L; Chan JF; Huang Y; Wang M; Luo Y; Yu J; Chu H; Chik KK; Yuen TT; Yin MT; Sobieszczyk ME; Huang Y; Yuen KY; Wang HH; Sheng Z; Ho DD
Nature; 2022 Apr; 604(7906):553-556. PubMed ID: 35240676
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants.
Cho J; Shin Y; Yang JS; Kim JW; Kim KC; Lee JY
Antiviral Res; 2023 Jun; 214():105609. PubMed ID: 37086978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
